U.S. patent application number 11/798079 was filed with the patent office on 2008-03-06 for indoline-sulfonamides compounds.
This patent application is currently assigned to Taipei Medical University. Invention is credited to Jang-Yang Chang, Hsing-Pang Hsieh, Jing-Ping Liou.
Application Number | 20080058386 11/798079 |
Document ID | / |
Family ID | 38219392 |
Filed Date | 2008-03-06 |
United States Patent
Application |
20080058386 |
Kind Code |
A1 |
Liou; Jing-Ping ; et
al. |
March 6, 2008 |
Indoline-sulfonamides compounds
Abstract
A series of indoline-sulfonamide compounds is disclosed. The
formula of indoline-sulfonamide compounds is shown as formula (I).
In formula (I), R.sup.1 is H or halogen; R.sup.2 is Ar, Ar--C(O)--,
Ar--CH.sub.2--, Ar--SO.sub.2--, Ar--O--C(O), ##STR00001## or
R''--C(O)--, and Ar is a substituted or unsubstituted C5-C20 aryl,
cyclyl, heterocyclyl, or heteroaryl, R' and R'' independently is
C1-C10 alkyl, or C1-C10 alkoxyl; and R.sup.3 is C5-C15 aryl or
C1-C10 alkyl. The indoline-sulfonamide compounds disclosed in the
present invention are characterized in inhibiting tubulin
polymerization, and treating cancers and other tubulin
polymerization-related disorders with a suitable pharmaceutical
acceptable carrier.
Inventors: |
Liou; Jing-Ping; (Taipei
City, TW) ; Chang; Jang-Yang; (Taipei City, TW)
; Hsieh; Hsing-Pang; (Taipei City, TW) |
Correspondence
Address: |
BACON & THOMAS, PLLC
625 SLATERS LANE, FOURTH FLOOR
ALEXANDRIA
VA
22314
US
|
Assignee: |
Taipei Medical University
Taipei
TW
National Health Research Institutes
Miaoli County
TW
|
Family ID: |
38219392 |
Appl. No.: |
11/798079 |
Filed: |
May 10, 2007 |
Current U.S.
Class: |
514/339 ;
514/414; 514/415; 546/277.7; 548/465; 548/469 |
Current CPC
Class: |
A61P 35/00 20180101;
A61P 43/00 20180101; C07D 405/12 20130101; C07D 409/12 20130101;
A61P 31/10 20180101; C07D 209/08 20130101; A61P 9/00 20180101; C07D
401/12 20130101 |
Class at
Publication: |
514/339 ;
514/414; 514/415; 546/277.7; 548/465; 548/469 |
International
Class: |
A61K 31/404 20060101
A61K031/404; A61K 31/44 20060101 A61K031/44; A61P 35/00 20060101
A61P035/00; C07D 209/04 20060101 C07D209/04; C07D 401/02 20060101
C07D401/02; C07D 405/00 20060101 C07D405/00 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 31, 2006 |
TW |
095132140 |
Claims
1. An indoline-sulfonamide compound as the following formula (I):
##STR00027## wherein R.sup.1 is H, or halogen; R.sup.2 is Ar,
Ar--C(O)--, Ar--CH.sub.2--, Ar--SO.sub.2--, Ar--O--C(O),
##STR00028## R''--C(O)--, and Ar is substituted or unsubstituted
C5-C20 aryl, cyclyl, heterocyclyl, or heteroaryl, R' and R''
independently, is C1-C10 alkyl, or C1-C10 alkoxyl; and R.sup.3 is
C5-C15 aryl or C1-C10 alkyl.
2. The compound as claimed in claim 1, wherein the hetero-atom of
the heterocyclyl or heteroaryl is N, O, or S.
3. The compound as claimed in claim 1, wherein the heteroaryl is
##STR00029##
4. The compound as claimed in claim 1, wherein R.sup.1 is H or
Br.
5. The compound as claimed in claim 1, wherein Ar is unsubstituted
phenyl.
6. The compound as claimed in claim 1, wherein Ar is substituted or
unsubstituted C5-C8 aryl or heteroaryl.
7. The compound as claimed in claim 1, wherein Ar is aryl with a
substituent, and the substituent is halogen, nitro, cyano, alkoxyl,
acetoxyl (CH.sub.3CO.sub.2.sup.-), or oxyl.
8. The compound as claimed in claim 1, wherein the halogen is F,
Cl, or Br.
9. The compound as claimed in claim 1, wherein R.sup.2 is benzoyl,
fluorobenzoyl, nitrobenzoyl, cyanobenzoyl, methoxybenzoyl, or
acetylbenzoy.
10. The compound as claimed in claim 1, wherein R.sup.2 is
isonicotinoyl, N-oxide-isonicotinoyl, furoyl, or thienoyl.
11. The compound as claimed in claim 1, wherein R.sup.2 is
benzenesulfonyl, nitrobenzenesulfonyl, or
fluorobenzenesulfonyl.
12. The compound as claimed in claim 1, wherein R.sup.2 is
(CO)OC.sub.6H.sub.5, or (CO)N(CH.sub.3)C.sub.6H.sub.5.
13. The compound as claimed in claim 1, wherein R.sup.2 is benzyl,
acetyl, or pivaloyl.
14. The compound as claimed in claim 1, wherein R.sup.3 is C1-C10
alkyl.
15. The compound as claimed in claim 14, wherein R.sup.3 is
methyl.
16. The compound as claimed in claim 1, wherein the compound is
1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-ylamine.
17. The compound as claimed in claim 1, wherein the compound is
1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-ylamine,
4-Fluoro-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benz-
amide,
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-4-nitro-
-benzamide,
4-Cyano-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benza-
mide,
4-Methoxy-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol
-7-yl]-benzamide, or
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-terephthalami-
c acid methyl ester.
18. The compound as claimed in claim 1, wherein the compound is
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinami-
de, Furan-2-carboxylic acid
[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro -1H-indol-7-yl]-amide,
or Thiophene-2-carboxylic acid
[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-amide.
19. The compound as claimed in claim 1, wherein the compound is
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benzenesulfon-
amide,
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-4-nitro-
-benzenesulfonamide, or
4-Fluoro-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benz-
enesulfonamide.
20. The compound as claimed in claim 1, wherein the compound is
[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-carbamic
acid phenyl ester, or
3-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-1-methyl-1-ph-
enyl-urea.
21. The compound as claimed in claim 1, wherein the compound is
Benzyl-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-amine,
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-acetamide,
or
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-2,2-dimethyl--
propionamide.
22. The compound as claimed in claim 1, wherein the compound is
N-[5-Bromo-1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isoni-
cotinamide, Furan-2-carboxylic acid
[5-bromo-1-(4-methoxy-benzenesulfonyl)
-2,3-dihydro-1H-indol-7-yl]-amide, or
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-N-oxide-isoni-
cotinamide.
23. The compound as claimed in claim 1, wherein the compound is
used for inhibiting cellular tubulin polymerization.
24. The compound as claimed in claim 1, wherein the compound is
used for inhibiting a tubulin polymerization related cancer.
25. The compound as claimed in claim 1, wherein the compound is
combined with a pharmaceutically acceptable carrier to provide a
pharmaceutical composition.
Description
BACKGROUND OF THE INVENTION
[0001] 1. Field of the Invention
[0002] The present invention relates to an indoline-sulfonamide
compound and, more particularly, to an indoline-sulfonamide
compound for inhibiting tubulin polymerization.
[0003] 2. Description of Related Art
[0004] The microtubule system of eukaryotic cells is an important
target for the development of anticancer agents. For a more
concrete description, the tubulin polymerization/depolymerization
is a popular target for the development of new chemotherapy agents.
A number of clinically used agents (such as paclitaxel, epothilone
A, vinblastine, combretastatin A-4 (CA-4), dolastatin 10, and
colchicines), taking tubulin polymerization/depolymerization as the
target, all exhibit their anticancer properties by disrupting
cellular microtubule structure and function resulting in mitotic
arrest, as well as inhibiting the growth of epithelium of newly
formed vasculature to shut down the blood supply to tumors (please
refer to Jordan et. al., (1998) Med. Res. Rev. 18: 259-296).
[0005] Therefore, according to the microtubule system (such as
tubulin polymerization/depolymerization) as the target for
developing compounds, the new therapy used for the treatment or the
prevention of cancers or cancer related symptoms, or the treatment
of angiogenesis related disease, such as cardiovascular disease
(e.g. atherosclerosis), chronic inflammation (e.g. rheumatoid
arthritis or Crohn's disease), diabetes (e.g. diabetic
retinopathy), psoriasis, and retinal neovascularization or corneal
neovascularization can be developed (please refer to Griggs rt.
al., (2002) Am. J. Pathol. 160(3): 1097-1103).
[0006] A variety of synthetic small molecules have been reported as
inhibitors of tubulin polymerization, which compete the
colchicine-binding site to tubulin. Structurally, they involve
various heteroaromatic cores, for instance including the indole,
benzothiophene, benzofuran, imidazole, thiazole, and oxadiazoline
moieties. The indole system has a majority, for example
2-aroylindoles, 3-aroylindoles, 3-aroyl-2-phenylindoles,
3-arylthioindoles-2-carboxylate, and indolyl-3-glyoxamides that
show strong antiproliferative and antitubulin activity.
[0007] The sulfonamide-containing compounds, such as N-pyridinyl
sulfonamide ABT-751 (formerly E-7010) and styryl-pyridine N-oxide
sulfonamide HMN-21416, demonstrated effective inhibitor of tubulin
polymerization and a potent antimitotic agent, respectively.
ABT-751 and HMN-214 are now undergoing human clinical trials
against various tumor types. So far, there have been no reports on
the inhibition of tubulin polymerization by
Indoline-sulfonamides.
SUMMARY OF THE INVENTION
[0008] The present invention relates to a novel
7-aroylaminoindoline-1-sulfonamide series as highly potent
inhibitors of tubulin polymerization.
[0009] The present invention provides an indoline-sulfonamide
compound as the following formula (I):
##STR00002##
[0010] wherein R.sup.1 is H, or halogen;
[0011] R.sup.2 is Ar, Ar--C(O)--, Ar--CH.sub.2--, Ar--SO.sub.2--,
Ar--O--C(O),
##STR00003##
R''--C(O)--, and Ar is substituted or unsubstituted C5-C20 aryl,
cyclyl, heterocyclyl, or heteroaryl, R' and R'' independently is
C1-C10 alkyl, or C1-C10 alkoxyl; and
[0012] R.sup.3 is C5-C15 aryl or C1-C10 alkyl.
[0013] The hetero-atom of the heterocyclyl or heteroaryl is not
limited. Preferably, the hetero-atom is N, O, or S. Preferably, the
heteroaryl is
##STR00004##
[0014] Preferably, R.sup.1 is H, or halogen (e.g. F, Cl, Br, I).
More preferably, R.sup.1 is H or Br.
[0015] The structure of Ar is not limited. Preferably, Ar is
unsubstituted phenyl, substituted or unsubstituted C5-C8 aryl or
heteroaryl, or aryl with a substituent. Preferably, the substituent
is halogen, nitro, cyano, alkoxyl, oxyl, or acetoxyl
(CH.sub.3CO.sub.2.sup.-). Preferably, the halogen is F, Cl, or
Br.
[0016] Preferably, R.sup.2 is benzoyl, fluorobenzoyl, nitrobenzoyl,
cyanobenzoyl, methoxybenzoyl, acetylbenzoyl, isonicotinoyl,
N-oxide-isonicotinoyl, furoyl, thienoyl, benzenesulfonyl,
nitrobenzenesulfonyl, fluorobenzenesulfonyl, (CO)OC.sub.6H.sub.5,
(CO)N(CH.sub.3)C.sub.6H.sub.5, benzyl, acetyl, or pivaloyl.
[0017] Preferably, R.sup.3 is C1-C10 alkyl. More preferably,
R.sup.3 is methyl.
[0018] The preferred examples of the indoline-sulfonamide compounds
of the present invention are: [0019]
1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-ylamine
(compound 19), [0020]
1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-ylamine
(compound 20), [0021]
4-Fluoro-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benz-
amide (compound 21), [0022]
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-4-nitro-benza-
mide (compound 22), [0023]
4-Cyano-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benza-
mide (compound 23), [0024]
4-Methoxy-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-ben-
zamide (compound 24), [0025]
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-terephthalami-
c acid methyl ester (compound 25), [0026]
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinami-
de (compound 26), [0027] Furan-2-carboxylic acid
[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro -1H-indol-7-yl]-amide
(compound 27), [0028] Thiophene-2-carboxylic acid
[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro -1H-indol-7-yl]-amide
(compound 28), [0029]
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benzenesulfon-
amide (compound 29), [0030]
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-4-nitro-benze-
nesulfonamide (compound 30), [0031]
4-Fluoro-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benz-
enesulfonamide (compound 31), [0032]
[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-carbamic
acid phenyl ester (compound 32), [0033]
3-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-1-methyl-1-ph-
enyl-urea (compound 33), [0034]
Benzyl-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-amine
(compound 34), [0035]
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-acetamide
(compound 35), [0036]
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-2,2-dimethyl--
propionamide (compound 36), [0037]
N-[5-Bromo-1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isoni-
cotinamide (compound 37), [0038] Furan-2-carboxylic acid
[5-bromo-1-(4-methoxy-benzenesulfonyl)
-2,3-dihydro-1H-indol-7-yl]-amide (compound 38), and [0039]
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-N-oxide-isoni-
cotinamide (compound 39).
[0040] The application field of the indoline-sulfonamide compounds
of the present invention is not limited. Preferably, the
indoline-sulfonamide compounds of the present invention are used
for inhibiting tubulin polymerization, and tubulin polymerization
related cancers or angiogenesis related diseases.
[0041] In addition, the present invention further provides a
pharmaceutical composition, comprising the indoline-sulfonamide
compound of the present invention and a pharmaceutically acceptable
carrier to inhibit tubulin polymerization, or tubulin
polymerization related cancers or diseases.
[0042] The indoline-sulfonamide compounds of the present invention
encompass the compounds themselves, their pharmaceutically
acceptable salts, and prodrugs thereof. For example, the salt can
be prepared by reacting the positive group (such as amino) of the
compound with an anion. The satiable anions include, but are not
limited to chloride, bromide, iodide, sulfate, nitrate, phosphate,
citrate, alkylsulfonate, trifluoroacetate, and acetate. Also, the
salt can be prepared by reacting the negative group (such as
carboxy) with a cation. The satiable cations include, but are not
limited to sodium, potassium, magnesium, calcium, and ammonium
(such as tetramethylammonium). The examples of the prodrugs include
the ester derivatives derived from the aforementioned compounds and
other pharmaceutically acceptable derivatives.
[0043] A non-aromatic double bond and one or more asymmetric
centers may exist in the indoline-sulfonamide compounds of the
present invention. The chemical structure depicted herein
encompasses meso compounds, racemic mixtures, enantiomers,
diastereomers, diastereomer mixtures, cis-isomers, and
trans-isomers. The present invention encompasses all isomeric
forms, including E-form isomers, and Z-form isomers.
[0044] The pharmaceutical composition comprising the
indoline-sulfonamide compounds of the present invention can be
administered intravenously, orally, nasally, rectally, locally, or
sublingually. Intravenous administration includes subcutaneous,
intraperitoneal, intravenous, intramuscular, intraarticular,
intraaortic, intrapleural, spinal, intrathecal, local injection at
the site attacked by a disease, or other suitable administration
techniques.
[0045] The sterile injectable composition can be a solution, or
suspension in a non-toxic intravenous diluent or solvent (such as
1,3-butanediol). The acceptable carrier or solvent can be mannitol
or water. In addition, the fixed oil is conventionally employed as
a solvent or suspending medium (such as synthetic mono- or
diglycerides). The fatty acid such as oleic acid and the glycerine
ester derivative thereof can be used in the preparation of
pharmaceutically acceptable injectables, such as olive oil or
castor oil, especially in polyoxyethylated form. The oily solution
or suspension can comprise long chain aliphatic alcohol diluents or
dispersion, carboxymethylcellulose, or a similar dispersion.
Examples of the generally used materials include surfactants (e.g.
Tween, or Spans), other similar emulsifying agents,
pharmaceutically acceptable solid, liquid generally used in the
pharmaceutical industry, or other bioavailable potentiating agents
used for developing new formulations.
[0046] The pharmaceutical composition may be in a form suitable for
oral use, for example, as capsule, troche, emulsifying agent,
liquid suspension, dispersion, or solvent. For administration in a
troche form, the generally used carrier is lactose or corn starch,
flotation reagent (e.g. magnesium stearate as an elementary
additive). For oral administration in a capsule form, the useful
diluents include lactose and corn starch. For oral administration
in a liquid suspension or emulsifying agent, the active material
can be suspended or dissolved in an oily medium containing an
emulsifying agent or suspension. If necessary, suitable
sweeteningagents, flavoring agents, or coloring agents can be
added.
[0047] Compositions intended for nasal aerosol or inhalation may be
prepared according to any method known to the art for the
manufacture of pharmaceutical compositions. For example, the
composition prepared in the isotonic sodium chloride solution can
further contain benzyl alcohol or other suitable preservative, an
absorbefacient to enhance bioavailability, fluorocarbon, or other
known soluble dispersion. The compositions comprising one or more
active compounds of the present invention may also be administered
in the form of suppositories for rectal administration of the
drug.
[0048] The carrier of the pharmaceutical composition containing
indoline-sulfonamide compounds must be acceptable. The term
"acceptable" means the carrier is compatible with the active
ingredient (more preferably, the carrier can stabilize the active
ingredient), and is not harmful to the patient. One or more agents
can be a pharmaceutical elixir which can deliver the active
compound of the present invention. Examples of other carriers
include silicon oxide, magnesium stearate, cellulose, sodium lauryl
sulfate, and D&C Yellow 10.
BRIEF DESCRIPTION OF THE DRAWINGS
[0049] none
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
[0050] The indoline-sulfonamide compounds of the present invention,
the analysis method thereof, and the determination method thereof
are presented in the following:
[0051] Melting points were determined on a Buchi (B-545) melting
point apparatus and are uncorrected.
[0052] Nuclear magnetic resonance (.sup.1H NMR and .sup.13C NMR)
spectra were obtained with the Bruker DRX-500 spectrometer
(operating at 500 MHz and at 125 MHz, respectively), Varian
Mercury-400 spectrometer (operating at 400 MHz and at 100 MHz,
respectively), and the Varian Mercury-300 spectrometer (operating
at 300 MHz and at 75 MHz, respectively), with chemical shift in
parts per million (ppm,.delta.) downfield from TMS as an internal
standard.
[0053] High-resolution mass spectra (HRMS) were measured with a
Finnigan (MAT-95XL) electron impact (EI) mass spectrometer.
[0054] Elemental analyses were performed on a Heraeus CHN--O Rapid
microanalyzer.
[0055] Flash column chromatography was done using silica gel (Merck
Kieselgel 60, No. 9385, 230-400 mesh ASTM).
[0056] All reactions were carried out under an atmosphere of dry
nitrogen.
[0057] The general method for the synthesis of
indoline-sulfonamides 19-38 is shown in Scheme 1.
##STR00005##
[0058] The preparation involved a straightforward reaction sequence
with high yields (overall 48-56% in three or four steps). The
commercially available 5-bromo-7-nitroindoline (16) was reacted
with the 4-methoxybenzenesulfonyl chloride in pyridine to afford
the 5-bromo-1-(4-methoxybenzenesulfonyl)-7-nitroindoline (17).
[0059] The reduction of 7-nitro group in 17 with Fe/NH.sub.4Cl in
isopropanol gave the corresponding 18, namely
7-amino-5-bromo-1-(4-methoxybenzenesulfonyl)indoline.
[0060] Compound 18 was converted to the
7-amino-1-(4-methoxybenzene-sulfonyl)indoline (19) by a free
radical-mediated debromination in the presence of AIBN and
Bu.sub.3SnH (as the pathway d in Scheme 1).
[0061] Compound 18 or 19 was further reacted with the corresponding
electrophiles in pyridine (as the pathway d in Scheme 1), including
aroyl chloride, heteroaroyl chloride, ArSO.sub.2Cl, ArO(CO)Cl,
ArN(CH.sub.3)(CO)Cl, benzyl chloride, acetyl anhydride and pivaloyl
chloride, to afford the desired 7-aminoindoline-1-sulfonamides
(20-25, 27-36 and 38, respectively).
[0062] 7-Isonicotinoyl substituted indolines, compound 26 and 37,
were obtained respectively by treatment of 19 and 18 with
isonicotinoyl chloride hydrochloride in the presence of
Cs.sub.2CO.sub.3 in anhydrous CH.sub.3CN (as the pathway e in
Scheme 1).
[0063] The synthesis of compounds 17-39 and the chemical properties
thereof are shown in the following examples.
EXAMPLE 1
5-Bromo-1-(4-methoxy-benzenesulfonyl)-7-nitro-2,3-dihydro-1H-indole
(17)
[0064] A solution of 5-bromo-7-nitroindoline (5 g, 0.021 mol),
4-methoxyphenylsulfonyl chloride (6.36 g, 0.030 mol) in pyridine
(10 ml) was stirred at 120.degree. C. for 16 h. The reaction was
quenched with water and extracted with CH.sub.2Cl.sub.2. The
combined organic layer was dried over anhydrous MgSO.sub.4 and
evaporated to give a residue that was chromatographed over silica
gel (EtOAc:n-hexane=1:2) to afford compound 17, yield 85%.
[0065] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 2.67 (t, J=7.8 Hz,
2H), 3.87 (s, 3H), 4.05 (t, J=7.5 Hz, 2H), 6.92-6.97 (m, 1H), 7.50
(d, J=1.5 Hz, 1H), 7.62-7.66 (m, 2H), 7.89 (d, J=1.5 Hz, 1H).
[0066] .sup.13C NMR (CDCl.sub.3) .delta. 29.0, 51.8, 55.7, 114.4,
118.7, 126.4, 128.6, 129.4, 132.0, 134.7, 141.7, 142.5, 163.8.
[0067] MS (ESI) m/z: 436 (M+23).sup.+.
EXAMPLE 2
5-Bromo-1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl
amine (18)
[0068] A mixture of 17 (9 g, 0.021 mol), iron (3.65 g, 0.065 mol),
and ammonium chloride (2.33 g, 0.043 mol) in isopropanol (200
ml)-water (50 ml) was stirred at 100.degree. C. for 4 h. After
cooling, the reaction mixture was filtrated and extracted with
CH.sub.2Cl.sub.2. The combined organic layer was dried by
MgSO.sub.4 and evaporated to give a residue that was purified by
silica gel flash column chromatography (EtOAc:n-hexane=2:3) to
afford compound 18, yield 89%.
[0069] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 2.13 (t, J=7.6 Hz,
2H), 3.84 (s, 3H), 3.95 (t, J=7.6 Hz, 2H), 4.80 (s, 2H), 6.53 (d,
J=2.0 Hz, 1H), 6.74 (d, J=2.0 Hz, 1H), 6.85-6.89(m, 2H), 7.54-7.57
(m, 2H).
[0070] .sup.13C NMR (CDCl.sub.3) .delta. 28.9, 53.2, 55.5, 114.1,
117.0, 118.1, 120.4, 127.1, 128.0, 129.6, 140.4, 141.5, 163.5.
[0071] MS (ESI) m/z: 384 (M+1).sup.+, 385(M+2).sup.+.
EXAMPLE 3
1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-ylamine
(19)
##STR00006##
[0073] To a stirred solution of 18 (2 g, 4.84 mmol), AIBN (0.08 g,
0.48 mmol), Bu.sub.3SnH (3.91 ml, 14.50 mmol) in toluene (49 ml)
was heated to reflux for 15 h. After cooling, the reaction mixture
was evaporated and then extracted by CH.sub.2Cl.sub.2. The combined
organic layer was dried by MgSO.sub.4 and concentrated to give a
residue that was purified by silica gel flash column chromatography
(EtOAc:n-hexane=1:2) to give compound 19, yield 90%.
[0074] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 2.15 (t, J=7.4 Hz,
2H), 3.82 (s, 3H), 3.95 (t, J=7.4 Hz, 2H), 6.42 (d, J=7.4 Hz, 1H),
6.59 (d, J=7.9 Hz, 1H), 6.81-6.84 (m, 2H), 6.90 (t, J=7.6 Hz, 1H),
7.51-7.54 (m, 2H).
[0075] MS (EI) m/z: 304 (M.sup.+, 6%), 133 (100%). HRMS (EI) for
C.sub.15H.sub.16N.sub.2O.sub.3S (M.sup.+): calcd, 304.0881; found,
304.0880.
EXAMPLE 4
1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-ylamine
(20)
##STR00007##
[0077] To a solution of 19 (0.1 g, 0.26 mmol), benzoyl chloride
(0.09 ml, 0.78 mmol) in pyridine (1 ml) was stirred at
100-110.degree. C. for 16 h. The reaction mixture was quenched with
ice water and extracted with EtOAc. The combined organic layer was
dried over anhydrous MgSO.sub.4 and evaporated to give residue that
was chromatographed over silica gel (EtOAc:n-hexane=1:2) to afford
20, yield 82%.
[0078] mp 205-206.degree. C.
[0079] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 2.25 (t, J=7.6 Hz,
2H), 3.84 (s, 3H), 4.03 (t, J=7.6 Hz, 2H), 6.83-6.87 (m, 3H), 7.20
(t, J=7.6 Hz, 1H), 7.48-7.57 (m, 5H), 8.06-8.09 (m, 2H), 8.27 (d,
J=8.0 Hz, 1H), 10.23 (s, 1H).
[0080] .sup.13C NMR (CDCl.sub.3) .delta. 29.0, 53.4, 55.6, 114.2,
120.5, 121.9, 127.4, 127.6, 128.6, 129.7, 130.5, 131.7, 131.8,
132.2, 134.6, 138.2, 163.8, 165.6.
[0081] MS (EI) m/z: 408 (M.sup.+, 7%), 237 (62%), 105 (100%). HRMS
(EI) for C.sub.22H.sub.20N.sub.2O.sub.4S (M.sup.+): calcd,
408.1136; found, 408.1140. Anal.
(C.sub.22H.sub.20N.sub.2O.sub.4S)C, H, N, S.
EXAMPLE 5
4-Fluoro-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benza-
mide (21)
##STR00008##
[0083] The title compound was obtained in 78% yield in a manner
similar for the preparation of 20 by use of 4-fluorobenzoyl
chloride.
[0084] mp 184-185.degree. C.
[0085] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 2.25 (t, J=7.5 Hz,
2H), 3.83 (s, 3H), 4.02 (t, J=7.5 Hz, 2H), 6.83-6.87 (m, 3H),
7.14-7.22 (m, 3H), 7.47-7.52 (m, 2H), 8.06-8.11 (m, 2H), 8.24 (d,
J=8.1 Hz, 1H), 10.2 (s, 1H).
[0086] MS (EI) m/z: 426 (M.sup.+, 11%), 255 (95%), 123 (100%). HRMS
(EI) for C.sub.22H.sub.19N.sub.2O.sub.4FS (M.sup.+): calcd,
426.1046; found, 426.1048.
EXAMPLE 6
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-4-nitro-benzam-
ide (22)
##STR00009##
[0088] The title compound was obtained in 90% yield in a manner
similar for the preparation of 20 by use of 4-nitrobenzoyl
chloride. mp 151-152.degree. C.
[0089] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 2.28 (t, J=7.5 Hz,
2H), 3.84 (s, 3H), 4.04 (t, J=7.5 Hz, 2H), 6.84-6.91 (m, 3H), 7.23
(t, J=7.8 Hz, 1H), 7.48-7.53 (m, 2H), 8.21-8.26 (m, 3H), 8.34-8.38
(m, 2H), 10.4 (s, 1H).
[0090] .sup.13C NMR (CDCl.sub.3) .delta. 29.0, 53.5, 55.6, 114.3,
121.2, 121.8, 123.9, 127.4, 127.8, 128.6, 129.6, 130.9, 132.3,
138.4, 140.1, 149.8, 163.4, 163.9.
[0091] MS (EI) m/z: 453 (M.sup.+, 100%), 282 (100%), 150 (65%).
HRMS (EI) for C.sub.22H.sub.19N.sub.3O.sub.6S (M.sup.+): calcd,
453.0993; found, 453.0994. Anal. (C.sub.22H.sub.19N.sub.3O.sub.6S)
C, H, N, S.
EXAMPLE 7
4-Cyano-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benzam-
ide (23)
##STR00010##
[0093] The title compound was obtained in 86% yield in a manner
similar for the preparation of 20 by use of 4-cyanobenzoyl
chloride.
[0094] mp 179-180.degree. C.
[0095] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 2.27 (t, J=7.2 Hz,
2H), 3.84 (s, 3H), 4.04 (t, J=7.5 Hz, 2H), 6.85-6.90 (m, 3H), 7.22
(t, J=8.1 Hz, 1H), 7.49-7.51 (m, 2H), 7.80-7.82 (m, 2H), 8.16-8.18
(m, 2H), 8.24 (d, J=8.1 Hz, 1H).
[0096] .sup.13C NMR (CDCl.sub.3) .delta. 29.2, 53.7, 55.9, 114.5,
115.7, 118.3, 121.3, 122.1, 127.6, 128.0, 128.3, 129.8, 131.2,
132.5, 132.8, 138.7, 138.8, 163.9, 164.2.
[0097] MS (EI) m/z: 433 (M.sup.+, 12%), 262 (100%), 130 (73%). HRMS
(EI) for C.sub.23H.sub.19N.sub.3O.sub.4S (M.sup.+): calcd,
433.1098; found, 433.1097. Anal. (C.sub.23H.sub.19N.sub.3O.sub.4S)
C, H, N, S.
EXAMPLE 8
4-Methoxy-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl
]-benzamide (24)
##STR00011##
[0099] The title compound was obtained in 75% yield in a manner
similar for the preparation of 20 by use of 4-methoxybenzoyl
chloride.
[0100] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 2.24 (t, J=7.5 Hz,
2H), 3.83 (s, 3H), 3.87 (s, 3H), 4.02 (t, J=7.8 Hz, 2H), 6.80-6.86
(m, 3H), 6.98-7.02 (m, 2H), 7.18 (t, J=8.1 Hz, 1H), 7.48-7.53 (m,
2H), 8.02-8.07 (m, 2H), 8.26 (d, J=8.1 Hz, 1H), 10.15 (s, 1H).
[0101] .sup.13C NMR (CDCl.sub.3) .delta. 29.0, 53.4, 55.2, 55.4,
113.7, 113.8, 114.2, 120.2, 121.8, 126.3, 126.8, 129.3, 129.6,
131.8, 131.9, 138.2, 162.4, 163.7, 165.1.
[0102] MS (EI) m/z: 438 (M.sup.+, 4%), 267 (28%), 135 (100%). HRMS
(EI) for C.sub.23H.sub.22N.sub.2O.sub.5S (M.sup.+): calcd,
438.1237; found, 438.1243.
EXAMPLE 9
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-terephthalamic
acid methyl ester (25)
##STR00012##
[0104] The title compound was obtained in 81% yield in a manner
similar for the preparation of 20 by use of methyl
4-chlorocarbonylbenzoate. mp 166-167.degree. C.
[0105] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 2.25 (t, J=7.5 Hz,
2H), 3.82 (s, 3H), 3.94 (s, 3H), 4.02 (t, J=7.5 Hz, 2H), 6.82-6.87
(m, 3H), 7.20 (t, J=7.5 Hz, 1H), 7.47-7.52 (m, 2H), 8.11-8.18 (m,
4H), 8.26 (d, J=7.8 Hz, 1H).
[0106] .sup.13C NMR (CDCl.sub.3) .delta. 28.9, 52.2, 53.3, 55.5,
114.2, 120.8, 121.7, 127.3, 127.4, 127.6, 129.5, 129.8, 131.1,
132.1, 132.8, 138.3, 138.4, 163.7, 164.4, 166.2.
[0107] MS (EI) m/z: 466 (M.sup.+, 14%), 295 (100%), 163 (89%). HRMS
(EI) for C.sub.24H.sub.22N.sub.2O.sub.6S (M.sup.+): calcd,
466.1194; found, 466.1196.
EXAMPLE 10
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotin
amide (26)
##STR00013##
[0109] To a stirred mixture of 19 (0.2 g, 0.52 mmol), isonicotinoyl
chloride hydrochloride (0.18 g, 1.04 mmol), and cesium carbonate
(0.68 g, 2.08 mmol) in acetonitrile (20 ml) was heated to reflux
for 16 h. The reaction mixture was quenched with ice water and
extracted with CH.sub.2Cl.sub.2. The combined organic layer was
dried over MgSO.sub.4 and evaporated to give a residue that was
purified by silica gel flash column chromatography (EtOAc:n-hexane
:NH.sub.3(aq)=3:2:1%) and recrystallized (CH.sub.2Cl.sub.2/EtOAc)
to afford compound 26, yield 82%.
[0110] mp 219-220.degree. C. (HCl salt).
[0111] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 2.23 (t, J=7.3 Hz,
2H), 3.79 (s, 3H), 3.99 (t, J=7.4 Hz, 2H), 6.81-6.85 (m, 3H), 7.17
(t, J=7.8 Hz, 1H), 7.46 (d, J=8.8 Hz, 2H), 7.87 (d, J=5.7 Hz, 2H),
8.21 (d, J=8.2 Hz, 1H), 8.77 (d, J=5.6 Hz, 2H), 10.35 (s, 1H).
[0112] .sup.13C NMR (CDCl.sub.3) .delta. 28.8, 53.3, 55.5, 114.2,
120.9, 121.1, 121.7, 127.2, 127.6, 129.4, 130.7, 132.1, 138.3,
141.5, 150.6, 163.3, 163.8.
[0113] MS (EI) m/z: 409 (M.sup.+, 36%), 314 (15%), 238 (100%). HRMS
(EI) for C.sub.21H.sub.19N.sub.3O.sub.4S (M.sup.+): calcd,
409.1094; found, 409.1095. Anal. (C.sub.21H.sub.19N.sub.3O.sub.4S)
C, H, N, S.
EXAMPLE 11
Furan-2-carboxylic acid [1-(4-methoxy-benzenesulfonyl)-2,3-dihydro
-1H-indol-7-yl]-amide (27)
##STR00014##
[0115] The title compound was obtained in 86% yield in a manner
similar for the preparation of 20 by use of 2-furoyl chloride.
[0116] mp 163-164.degree. C.
[0117] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 2.24 (t, J=7.6 Hz,
2H), 3.83 (s, 3H), 4.03 (t, J=7.2 Hz, 2H), 6.53-6.55 (m, 1H),
6.83-6.87 (m, 3H), 7.18 (t, J=7.6 Hz, 1H), 7.25-7.26 (m, 1H),
7.48-7.52 (m, 2H), 7.60 (m, 1H), 8.22 (d, J=8.4 Hz, 1H), 10.25 (s,
1H).
[0118] .sup.13C NMR (CDCl.sub.3) .delta. 29.0, 53.3, 55.6, 112.0,
114.2, 115.0, 120.5, 121.7, 127.6, 127.7, 129.7, 131.0, 132.1,
138.3, 144.9, 148.0, 156.6, 163.7.
[0119] MS (EI) m/z: 398 (M.sup.+, 13%), 303 (10%), 227 (100%). HRMS
(EI) for C.sub.20H.sub.18N.sub.2O.sub.5S (M.sup.+): calcd,
398.0933; found, 398.0935. Anal. (C.sub.20H.sub.18N.sub.2O.sub.5S)
C, H, N, S.
EXAMPLE 12
Thiophene-2-carboxylic acid
[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro -1H-indol-7-yl]-amide
(28)
##STR00015##
[0121] The title compound was obtained in 78% yield in a manner
similar for the preparation of 20 by use of 2-thenoyl chloride.
[0122] mp 188-189.degree. C.
[0123] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 2.26 (t, J=7.6 Hz,
2H), 3.83 (s, 3H), 4.03 (t, J=7.6 Hz, 2H), 6.82-6.87 (m, 3H),
7.12-7.15 (m, 1H), 7.17 (t, J=7.6 Hz, 1H), 7.49-7.53 (m, 2H), 7.55
(dd, J=5.2 Hz, 1.2 Hz, 1H), 7.82 (dd, J=4.0, 1.2 Hz, 1H), 8.22 (d,
J=8.0 Hz, 1H), 10.23 (s, 1H).
[0124] .sup.13C NMR (CDCl.sub.3) .delta. 29.0, 53.5, 55.6, 114.2,
120.4, 121.5, 127.5, 127.6, 127.9, 128.5, 129.6, 130.9, 131.2,
131.8, 138.2, 140.0, 160.1, 163.8.
[0125] MS (EI) m/z: 414 (M.sup.+, 13%), 243 (100%), 111 (73%). HRMS
(EI) for C.sub.20H.sub.18N.sub.2O.sub.4S.sub.2 (M.sup.+): calcd,
414.0704; found, 414.0706. Anal.
(C.sub.20H.sub.18N.sub.2O.sub.4S.sub.2) C, H, N, S.
EXAMPLE 13
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benzenesulfona-
mide (29)
##STR00016##
[0127] The title compound was obtained in 80% yield in a manner
similar for the preparation of 20 by use of benzenesulfonyl
chloride. mp 143-145.degree. C.
[0128] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 2.09 (t, J=7.2 Hz,
2H), 3.53 (t, J=7.5 Hz, 2H), 3.80 (s, 3H), 6.77 (d, J=8.7 Hz, 2H),
6.84 (d, J=7.2 Hz, 1H), 7.11 (t, J=7.5 Hz, 1H), 7.27-7.32 (m, 2H),
7.40 (m, 2H), 7.49-7.54 (m, 2H), 7.75 (d, J=7.8 Hz, 1H).
[0129] .sup.13C NMR (CDCl.sub.3) .delta. 28.7, 52.7, 55.6, 114.2,
122.3, 124.2, 127.3, 127.7, 128.5, 129.3, 129.4, 129.6, 132.5,
134.9, 138.3, 139.5, 163.7.
[0130] MS (EI) m/z: 444 (M.sup.+, 10%), 273 (85%), 132 (100%). HRMS
(EI) for C.sub.21H.sub.20N.sub.2O.sub.5S.sub.2 (M.sup.+): calcd,
444.0812; found, 444.0813.
EXAMPLE 14
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-4-nitro-benzen-
esulfonamide (30)
##STR00017##
[0132] The title compound was obtained in 82% yield in a manner
similar for the preparation of 20 by use of 4-nitrobenzenesulfonyl
chloride.
[0133] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 2.12 (t, J=7.2 Hz,
2H), 3.53 (t, J=7.2 Hz, 2H), 3.82 (s, 3H), 6.79-6.83 (m, 2H), 6.92
(dd, J=7.6, 1.2 Hz, 1H), 7.16 (t, J=7.6 Hz, 1H), 7.30-7.34 (m, 2H),
7.52 (d, J=8.0 Hz, 1H), 7.94-7.97 (m, 2H), 8.24-8.28 (m, 2H), 9.16
(s, 1H).
[0134] .sup.13C NMR (CDCl.sub.3) .delta. 28.7, 52.8, 55.6, 114.3,
123.2, 123.7, 124.8, 127.0, 128.0, 128.4, 128.7, 129.4, 135.2,
138.5, 145.5, 149.9, 163.9.
[0135] MS (EI) m/z: 489 (M.sup.+, 13%), 318 (100%), 132 (72%). HRMS
(EI) for C.sub.21H.sub.19N.sub.3O.sub.7S.sub.2 (M.sup.+): calcd,
489.0654; found, 489.0659.
EXAMPLE 15
4-Fluoro-N-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-benze-
nesulfonamide (31)
##STR00018##
[0137] The title compound was obtained in 83% yield in a manner
similar for the preparation of 20 by use of 4-fluorobenzenesulfonyl
chloride. mp 104-105.degree. C.
[0138] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 2.11 (t, J=7.5 Hz,
2H), 3.58 (t, J=7.8 Hz, 2H), 3.81 (s, 3H), 6.77-6.81 (m, 2H), 6.86
(dd, J=7.8, 1.2 Hz, 1H), 7.05-7.15 (m, 3H), 7.30-7.34 (m, 2H), 7.50
(d, J=8.0 Hz, 1H), 7.75-7.80 (m, 2H), 8.97 (s, 1H).
[0139] MS (EI) m/z: 462 (M.sup.+, 13%), 291 (100%), 132 (59%). HRMS
(EI) for C.sub.21H.sub.19N.sub.2O.sub.5S.sub.2F (M.sup.+): calcd,
462.0729; found, 462.0724.
EXAMPLE 16
[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-carbamic
acid phenyl ester (32)
##STR00019##
[0141] The title compound was obtained in 76% yield in a manner
similar for the preparation of 20 by use of phenyl chloroformate.
mp 164-166.degree. C.
[0142] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 2.29 (t, J=7.8 Hz,
2H), 3.75 (s, 3H), 4.00 (t, J=7.5 Hz, 2H), 6.75-6.80 (m, 2H), 7.07
(dd, J=7.5, 0.6 Hz, 1H), 7.16-7.25 (m, 4H), 7.30-7.40 (m, 4H),
7.57-7.62 (m, 2H).
[0143] .sup.13C NMR (CDCl.sub.3) .delta. 29.0, 53.1, 55.5, 114.0,
121.5, 121.6, 125.1, 125.9, 127.0, 129.1, 129.2, 129.3, 129.6,
130.6, 138.9, 139.1, 150.7, 163.3.
[0144] MS (ESI) m/z: 425 (M+H).sup.+.
EXAMPLE 17
3-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-1-methyl-1-phe-
nyl-urea (33)
##STR00020##
[0146] The title compound was obtained in 75% yield in a manner
similar for the preparation of 20 by use of
N-methyl-N-phenylcarbamoyl chloride. mp 199-201.degree. C.
[0147] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 2.07 (t, J=7.2 Hz,
2H), 3.38 (s, 3H), 3.80 (s, 3H), 3.83 (t, J=7.2 Hz, 2H), 6.71 (d,
J=8.0 Hz, 1H), 6.75-6.78 (m, 2H), 7.12 (t, J=7.8 Hz, 1H), 7.29-7.33
(m, 2H), 7.35-7.39 (m, 1H), 7.40-7.43 (m, 2H), 7.48-7.52 (m, 2H),
7.93 (d, J=8.0 Hz, 1H), 8.28 (s, 1H).
[0148] .sup.13C NMR (CDCl.sub.3).delta. 28.8, 37.4, 53.0, 55.5,
113.9, 119.0, 122.0, 127.3, 127.6, 127.7, 127.8, 129.6, 130.0,
132.2, 132.9, 137.8, 142.6, 155.1, 163.5.
[0149] MS (EI) m/z: 437 (M.sup.+, 9%), 266 (100%), 159 (81%). HRMS
(EI) for C.sub.23H.sub.23N.sub.3O.sub.4S (M.sup.+): calcd,
437.1405; found, 437.1408.
EXAMPLE 18
Benzyl-[1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-amine
(34)
##STR00021##
[0151] The title compound was obtained in 85% yield in a manner
similar for the preparation of 20 by use of benzyl chloride. mp
162-163.degree. C.
[0152] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 1.98 (t, J=7.2 Hz,
2H), 3.75 (t, J=7.2 Hz, 2H), 3.77 (s, 3H), 4.72 (s, 3H), 6.42 (d,
J=7.2 Hz, 1H), 6.70-6.76 (m, 2H), 6.92 (t, J=7.5 Hz, 1H), 7.14-7.27
(m, 4H), 7.35-7.40 (m, 4H).
[0153] .sup.13C NMR (CDCl.sub.3) .delta. 28.7, 51.9, 55.3, 55.4,
113.7, 115.2, 118.4, 126.5, 127.7, 128.1, 128.9, 129.8, 130.4,
139.3, 139.4, 143.7, 163.2.
[0154] MS (ESI) m/z: 395 (M+H).sup.+.
EXAMPLE 19
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-acetamide
35)
##STR00022##
[0156] The title compound was obtained in 89% yield in a manner
similar for the preparation of 20 by use of acetic anhydride. mp
154-155.degree. C.
[0157] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 2.20 (t, J=7.5 Hz,
2H), 2.23 (s, 3H), 3.83 (s, 3H), 4.00 (t, J=7.5 Hz, 2H), 6.79 (d,
J=7.8 Hz, 1H), 6.82-6.86 (m, 2H), 7.13 (t, J=7.9 Hz, 1H), 7.44-7.48
(m, 2H), 8.10 (d, J=8.4 Hz, 1H), 8.35 (s, 1H).
[0158] .sup.13C NMR (CDCl.sub.3) .delta. 24.7, 28.9, 53.4, 55.6,
114.2, 120.2, 121.5, 127.5, 127.6, 129.5, 131.4, 131.5, 138.0,
163.7, 168.8.
[0159] MS (EI) m/z: 346 (M.sup.+, 18%), 175 (44%), 133 (100%). HRMS
(EI) for C.sub.17H.sub.18N.sub.2O.sub.4S (M.sup.+): calcd,
346.0979; found, 346.0983. Anal. (C.sub.17H.sub.18N.sub.2O.sub.4S)
C, H, N, S.
EXAMPLE 20
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-2,2-dimethyl-p-
ropionamide (36)
##STR00023##
[0161] The title compound was obtained in 87% yield in a manner
similar for the preparation of 20 by use of pivaloyl chloride.
[0162] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 1.37 (s, 9H), 2.19
(t, J=7.2 Hz, 2H), 3.83 (s, 3H), 3.98 (t, J=7.5 Hz, 2H), 6.79 (d,
J=7.5 Hz, 1H), 6.82-6.85 (m, 2H), 7.13 (t, J=7.8 Hz, 1H), 7.45-7.48
(m, 2H), 8.09 (d, J=8.1 Hz, 1H), 9.53 (s, 1H).
[0163] .sup.13C NMR (CDCl.sub.3) .delta. 27.6, 28.5, 39.9, 53.3,
55.6, 114.1, 120.1, 122.0, 127.5, 127.7, 129.7, 131.8, 132.1,
138.1, 163.7, 177.6.
[0164] MS (EI) m/z: 388 (M.sup.+, 13%), 217 (51%), 167 (100%). HRMS
(EI) for C.sub.20H.sub.24N.sub.2O.sub.4S (M.sup.+): calcd,
388.1449; found, 388.1453.
EXAMPLE 21
N-[5-Bromo-1-(4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonic-
otinamide (37)
##STR00024##
[0166] The title compound was obtained in 80% yield in a manner
similar for the preparation of 26 starting from compound 18.
[0167] mp 191-192.degree. C.
[0168] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 2.27 (t, J=7.2 Hz,
2H), 3.86 (s, 3H), 4.04 (t, J=7.5 Hz, 2H), 6.89-6.93 (m, 2H), 7.02
(d, J=1.8 Hz, 1H), 7.51-7.56 (m, 2H), 7.88-7.90 (m, 2H), 8.51 (d,
J=1.8 Hz, 1H), 8.82-8.84 (m, 2H), 10.3 (s, 1H).
[0169] .sup.13C NMR (CDCl.sub.3) .delta. 28.8, 53.6, 55.6, 114.5,
120.6, 120.9, 124.1, 124.3, 127.0, 129.5, 131.2, 131.8, 140.1,
141.1, 150.7, 163.4, 164.0.
[0170] MS (EI) m/z: 490(M.sup.++2, 3%), 489(M.sup.++1, 12%), 488
(M.sup.+, 3%), 487 (M.sup.+-1, 11%), 318 (100%), 316 (98%). HRMS
(EI) for C.sub.21H.sub.18N.sub.3O.sub.4SBr (M.sup.++1): calcd,
489.0178; found, 489.0180.
EXAMPLE 22
Furan-2-carboxylic acid [5-bromo-1-(4-methoxy-benzenesulfonyl)
-2,3-dihydro-1H-indol-7-yl]-amide (38)
##STR00025##
[0172] The title compound was obtained in 80% yield in a manner
similar for the preparation of 20 starting from compound 18. mp
170-171.degree. C.
[0173] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 2.23 (t, J=7.6 Hz,
2H), 3.86 (s, 3H), 4.03 (t, J=7.6 Hz, 2H), 6.55 (m, 1H), 6.88-6.91
(m, 2H), 6.97 (d, J=1.6 Hz, 1H), 7.26-7.27 (m, 1H), 7.52-7.56 (m,
2H), 7.61 (m, 1H), 8.49 (d, J=1.6 Hz, 1H), 10.24 (s, 1H).
[0174] .sup.13C NMR (CDCl.sub.3) .delta. 28.9, 53.5, 55.6, 112.2,
114.4, 115.5, 120.5, 123.5, 124.2, 127.4, 129.7, 131.1, 132.1,
140.0, 145.1, 147.6, 156.5, 163.9.
[0175] MS (EI) m/z: 479(M.sup.++2, 3%), 478(M.sup.++1, 13%), 477
(M.sup.+, 3%), 476 (M.sup.+-1, 12%), 307 (99%), 305 (100%). HRMS
(EI) for C.sub.20H.sub.17N.sub.2O.sub.5SBr (M.sup.++1): calcd,
478.0017; found, 478.0016.
EXAMPLE 23
N-[1-(4-Methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-N-oxide-isonic-
otinamide (39)
##STR00026##
[0177] To a solution of compound 26 (0.27 g, 0.24 mmol) and
m-chloroperbenzoic acid (0.3 g, 0.49 mmol) in EtOAc (10 ml) was
stirred at room temperature for 5 h. The reaction mixture was
quenched with NaHCO.sub.3 and extracted by CH.sub.2Cl.sub.2 (x3).
The combined organic layer was dried over anhydrous MgSO.sub.4 and
evaporated to give residue that was chromatographed over silica gel
(CH.sub.2Cl.sub.2: MeOH=15:1) to afford the desired compound 39,
yield 85%.
[0178] .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 2.29 (t, J=7.5 Hz,
2H), 3.84 (s, 3H), 4.05 (t, J=7.4 Hz, 2H), 6.84-6.91 (m, 3H), 7.22
(t, J=7.8 Hz, 1H), 7.50 (m, 2H), 7.97 (m, 2H), 8.21 (d, J=8.1 Hz,
1H), 8.29 (m, 2H), 10.38 (s, 1H).
[0179] .sup.13C NMR (CDCl.sub.3) .delta. 28.9, 53.5, 55.6, 114.3,
121.2, 121.6, 124.6, 127.2, 127.8, 129.5, 130.6, 130.9, 132.1,
138.4, 139.4, 161.2, 163.9.
[0180] MS (ESI) m/z: 426 (M+1).sup.+.
EXAMPLE 24
Elemental Analyses of Compounds 20, 22, 23, 26, 27, 28, and 35
TABLE-US-00001 [0181] calculated found Compd formula % C % H % N %
S % C % H % N % S 20 C.sub.22H.sub.20N.sub.2O.sub.4S 64.69 4.94
6.86 7.85 64.72 4.81 6.61 7.71 22 C.sub.22H.sub.19N.sub.3O.sub.6S
58.27 4.22 9.27 7.07 58.49 4.19 9.01 7.08 23
C.sub.23H.sub.19N.sub.3O.sub.4S 63.73 4.42 9.69 7.40 63.61 4.58
9.72 7.31 26 C.sub.21H.sub.19N.sub.3O.sub.4S 61.60 4.68 10.26 7.83
61.54 4.71 10.18 7.88 27 C.sub.20H.sub.18N.sub.2O.sub.5S 60.29 4.55
7.03 8.05 60.40 4.38 7.19 8.21 28
C.sub.20H.sub.18N.sub.2O.sub.4S.sub.2 57.95 4.38 6.76 15.47 58.01
4.25 6.78 15.29 35 C.sub.17H.sub.18N.sub.2O.sub.4S 58.94 5.24 8.09
9.26 58.86 5.28 7.88 9.14
EXAMPLE 25
Biological Test
[0182] Regents for cell culture were obtained from Gibco-BRL Life
Technologies (Gaitherburg, Md.). Microtubule-associated protein
(MAP)-rich tubulin was purchased from Cytoskeleton, Inc. (Denver,
Colo.). [.sup.3H]Colchicine (specific activity, 60-87 Ci/mmol) was
purchased from PerkinElmer Life Sciences (Boston, Mass.).
(a) Cell Growth Inhibitory Assay
[0183] Human oral epidermoid carcinoma KB cells, colorectal
carcinoma HT29 cells, non small cell lung carcinoma H460 cells, and
two stomach carcinoma TSGH, MKN45 cells were maintained in
RPMI-1640 medium supplied with 5% fetal bovine serum.
[0184] KB-VIN10 cells were maintained in growth medium supplemented
with 10 nM vincristine, generated from vincristine-driven
selection, and displayed overexpression of P-gp 170/MDR.
[0185] Cells in logarithmic phase were cultured at a density of
5000 cells/mL/well in a 24-well plate. KB-VIN10 cells were cultured
in drug-free medium for 3 days prior to use. The cells were exposed
to various concentrations of the test drugs for 72 h. The methylene
blue dye assay was used to evaluate the effect of the test
compounds on cell growth as described previously. The IC.sub.50
value resulting from 50% inhibition of cell growth was calculated
graphically as a comparison with the control.
[0186] The result of the examination shows that among the compounds
19-39 of the present invention, IC.sub.50 of at least seventeen
compounds is <5 .mu.M, and IC.sub.50 of the other compounds is
<10 nM.
[0187] (b) Tubulin Polymerization in Vitro Assay
[0188] Turbidimetric assays of microtubules were performed as
described by Bollag et al.
[0189] MAP-rich tubulin (2 mg/mL) in 100 mL buffer containing 100
mM PIPES (pH 6.9), 2 mM MgCl.sub.2, 1 mM GTP, and 2% (v/v) dimethyl
sulfoxide were placed in a 96-well microtiter plate in the presence
of test compounds. The increase in absorbance was measured at 350
nm in a PowerWave X Microplate Reader (BIO-TEK Instruments,
Winooski, Vt.) at 37.degree. C. and recorded every 30 s for 30 min.
The area under the curve (AUC) was used to determine the
concentration that inhibited tubulin polymerization to 50%
(IC.sub.50). The AUC of the untreated control and 10 .mu.M of
colchicine was set to 100% and 0% polymerization, respectively, and
the IC.sub.50 was calculated by nonlinear regression in at least
three experiments.
[0190] According to the results, the tested sulfonamide compounds
(<2 .mu.M, in the average) exhibit the property of inhibiting
tubulin polymerization.
[0191] Although the present invention has been explained in
relation to its preferred embodiment, it is to be understood that
many other possible modifications and variations can be made
without departing from the spirit and scope of the invention as
hereinafter claimed.
* * * * *